Segment Information (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Segment Information - Schedule of Segment Reporting Information by Segment

Information regarding the operations and assets of these reportable business segments is contained in the following table:

	Three months ended March 31,
Sale of Product	2022		2021
Radiochemical Products	$	1,625,923	$	661,177
Cobalt Products		171,906		118,373
Nuclear Medicine Standards		1,009,612		1,190,949
Fluorine Products		—		22,013
Total Segments		2,807,441		1,992,512
Corporate revenue		—		—
Total Consolidated	$	2,807,441	$	1,992,512

	Three months ended March 31,
Depreciation and Amortization	2022		2021
Radiochemical Products	$	41,930	$	79,547
Cobalt Products		12,141		13,639
Nuclear Medicine Standards		28,646		16,622
Fluorine Products		26,095		26,095
Total Segments		108,812		135,903
Corporate depreciation and amortization		10,306		4,299
Total Consolidated	$	119,118	$	140,202

	Three months ended March 31,
Segment Income (Loss)	2022			2021
Radiochemical Products	$	2,470,663		$	4,425
Cobalt Products		(13,075	)		(30,097	)
Nuclear Medicine Standards		37,716			263,318
Fluorine Products		(31,830	)		(33,514	)
Total Segments		2,463,474			204,132
Corporate loss		(1,208,429	)		(805,284	)
Net Income (Loss)	$	1,255,045		$	(601,152	)

	Three months ended March 31,
Expenditures for Segment Assets	2022		2021
Radiochemical Products	$	—	$	3,103
Cobalt Products		—		16,592
Nuclear Medicine Standards		51,100		135,000
Fluorine Products		—		4,060
Total Segments		51,100		158,755
Corporate purchases		—		—
Total Consolidated	$	51,100	$	158,755

	March 31,		December 31,
Segment Assets	2022		2021
Radiochemical Products	$	1,058,297	$	2,890,590
Cobalt Products		550,321		597,420
Nuclear Medicine Standards		1,412,533		2,259,759
Fluorine Products		5,230,023		5,258,823
Total Segments		8,251,174		11,006,592
Corporate assets		8,801,964		5,320,550
Total Consolidated	$	17,053,138	$	16,327,142